Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 436 to 450 of 537 results for syndrome

  1. microINR for anticoagulation therapy (MIB257)

    NICE has developed a medtech innovation briefing (MIB) on microINR for anticoagulation therapy .

    Medtech innovation briefing
    Published
    21 April 2021

  2. O2matic PRO 100 for optimising oxygen treatment in respiratory conditions (MIB308)

    NICE has developed a medtech innovation briefing (MIB) on O2matic PRO 100 for optimising oxygen treatment in respiratory conditions .

    Medtech innovation briefing
    Published
    11 October 2022

  3. Zanubrutinib for treating chronic lymphocytic leukaemia (TA931)

    Evidence-based recommendations on zanubrutinib (Brukinsa) for treating chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    22 November 2023
    View recommendations

    Sections for TA931

  4. Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA1065)

    Evidence-based recommendations on nivolumab (Opdivo) plus ipilimumab (Yervoy) for untreated unresectable or metastatic colorectal cancer with high microsatellite instability in adults.

    Technology appraisal guidance
    Published
    28 May 2025

    Sections for TA1065

  5. Atrial fibrillation: diagnosis and management (NG196)

    This guideline covers diagnosing and managing atrial fibrillation in adults. It includes guidance on providing the best care and treatment for people with atrial fibrillation, including assessing and managing risks of stroke and bleeding.

    NICE guideline
    Last updated
    30 June 2021
    View recommendations

    Sections for NG196

  6. Specialist neonatal respiratory care for babies born preterm (NG124)

    This guideline covers specific aspects of respiratory support (for example, oxygen supplementation, assisted ventilation, treatment of some respiratory disorders, and aspects of monitoring) for preterm babies in hospital.

    NICE guideline
    Published
    3 April 2019
    View recommendations

    Sections for NG124

  7. Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant (TA640)

    Evidence-based recommendations on treosulfan (Trecondi) with fludarabine for conditioning treatment before allogeneic haematopoietic stem cell transplant for malignant diseases in people for whom a reduced intensity regimen would be suitable.

    Technology appraisal guidance
    Published
    5 August 2020
    View recommendations

    Sections for TA640

  8. Diarrhoea and vomiting caused by gastroenteritis in under 5s: diagnosis and management (CG84)

    This guideline covers diagnosing, managing and referring infants and young children younger than 5 years who present with acute diarrhoea (lasting up to 14 days) with or without vomiting. It aims to improve the diagnosis and management of infective gastroenteritis and appropriate escalation of care.

    Clinical guideline
    Published
    22 April 2009
    View recommendations

    Sections for CG84

  9. NICE noted that the cost effectiveness of lenalidomide compared with standard care for people with low- or intermediate-1-risk MDS associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate, was sensitive to whether the patient access scheme would be realised in clinical practice. The Committee agreed that it would be critical to generate evidence to support the following: - The proportion of people who become eligible for the patient access scheme, that is, that they remain on treatment beyond 26 cycles. - The benefit of lenalidomide after 26 cycles, that is the associated overall survival and health related quality of life for those who remain on treatment beyond 26 cycles.

    Comes from guidance Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality...

    Research recommendation
    Published
    9 June 2015

  10. Digital technologies to support smoking cessation in secondary care patients: early value assessment

    In development Reference number: GID-HTE10061 Expected publication date: TBC

    In development

  11. Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions (MIB89)

    NICE has developed a medtech innovation briefing (MIB) on Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions .

    Medtech innovation briefing
    Published
    29 November 2016

  12. Newly diagnosed seizures (focal and generalised) – monotherapy: How do the newer AEDs compare in efficacy to the standard AEDs in the treatment of newly diagnosed epilepsy? Focal seizures: carbamazepine, eslicarbazepine acetate, lacosamide, lamotrigine, levetiracetam, pregabalin  and zonisamide. Generalised seizures: lamotrigine, levetiracetam, sodium valproate and zonisamide.

    trial all age groups subgroup analyses on seizure types and syndromes primary outcome of seizure freedom secondary outcomes, including

    Research recommendation
    Published
    13 August 2021

  13. Sipavibart for preventing COVID-19 [ID6282]

    In development Reference number: GID-TA11352 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. ClearWay RX for drug delivery to coronary artery thrombotic lesions (MIB55)

    NICE has developed a medtech innovation briefing (MIB) on ClearWay RX for drug delivery to coronary artery thrombotic lesions

    Medtech innovation briefing
    Published
    11 March 2016

  15. There is a need for further evidence on the long-term outcomes of treatment with eculizumab, and on the effect of treatment in children, adolescents and during pregnancy. The Committee supports enrolment of patients into the aHUS registry and the collection of high-quality information from these registries periodically to inform treatment decisions.

    from guidance Eculizumab for treating atypical haemolytic uraemic syndrome Number HST1 Date issued January 2015 Other details

    Research recommendation
    Published
    9 June 2015